Niagen Bioscience, Inc. NAGE
Medicinal Chemicals and Botanical Products · data as of November 13, 2026
Niagen Bioscience, Inc. (NAGE) is a healthcare company listed in the US with a market value of about $164M. In the twelve months to September 30, 2026 it had revenue of $122M and net income of $10M, a net margin of 8.4%.
Its overall Stock Analiz score is 2.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is shareholder returns (1/5).
Key numbers: a P/E of 17.2, 5-year revenue growth of 17% a year, a 5-year average ROIC of -17%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 55% below the current price.
About Niagen Bioscience
Niagen Bioscience is listed in the US and classified in medicinal chemicals and botanical products. Revenue went from $15M in 2014 to $129M in 2025, growth of about 21.4% a year. It was profitable in 2 of the last 10 years in our data. Its share count rose by 23% over three years (dilution for shareholders). It spends 5% of revenue on research and development.
Score: 2.4 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- ROE above 15%
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- Positive free cash flow
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $122M | $129M | $100M | $84M | $72M | $67M | $59M | $46M | $32M | $21M | $22M |
| Net income | $10M | $17M | $9M | -$5M | -$17M | -$27M | -$20M | -$32M | -$33M | -$11M | -$3M |
| Free cash flow | — | — | — | — | — | — | — | -$21M | -$22M | -$11M | -$4M |
| EPS (diluted) | $0.12 | $0.20 | $0.11 | $-0.07 | $-0.24 | $-0.40 | $-0.33 | $-0.56 | $-0.00 | $-0.00 | $-0.00 |
| Net margin | 8.4% | 13.4% | 8.6% | -5.9% | -23.0% | -40.2% | -33.6% | -69.5% | -105.6% | -53.7% | -13.5% |
| ROIC | — | 19.6% | 15.3% | -17.6% | -44.8% | -58.7% | -87.0% | -77.2% | -95.9% | -30.2% | -29.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is Niagen Bioscience’s P/E ratio?
About 17.2, based on the last twelve months of diluted earnings per share.
Is Niagen Bioscience stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 55% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Niagen Bioscience pay a dividend?
Not currently.
Is Niagen Bioscience a good stock to buy?
We do not give buy or sell advice. Niagen Bioscience scores 2.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.